These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24333551)

  • 1. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
    Nakata D; Masaki T; Tanaka A; Yoshimatsu M; Akinaga Y; Asada M; Sasada R; Takeyama M; Miwa K; Watanabe T; Kusaka M
    Eur J Pharmacol; 2014 Jan; 723():167-74. PubMed ID: 24333551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys.
    Hara T; Araki H; Kusaka M; Harada M; Cho N; Suzuki N; Furuya S; Fujino M
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1697-704. PubMed ID: 12679460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis.
    Kim SM; Yoo T; Lee SY; Kim EJ; Lee SM; Lee MH; Han MY; Jung SH; Choi JH; Ryu KH; Kim HT
    Life Sci; 2015 Oct; 139():166-74. PubMed ID: 26321528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats.
    Matsui H; Tanaka A; Yokoyama K; Takatsu Y; Ishikawa K; Asami T; Nishizawa N; Suzuki A; Kumano S; Terada M; Kusaka M; Kitada C; Ohtaki T
    Endocrinology; 2012 Nov; 153(11):5297-308. PubMed ID: 23027808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
    George DJ; Dearnaley DP
    Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
    Liu YF; Fu SQ; Yan YC; Gong BB; Xie WJ; Yang XR; Sun T; Ma M
    Drug Des Devel Ther; 2021; 15():639-649. PubMed ID: 33623372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
    MacLean DB; Shi H; Faessel HM; Saad F
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4579-87. PubMed ID: 26502357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.
    Miwa K; Hitaka T; Imada T; Sasaki S; Yoshimatsu M; Kusaka M; Tanaka A; Nakata D; Furuya S; Endo S; Hamamura K; Kitazaki T
    J Med Chem; 2011 Jul; 54(14):4998-5012. PubMed ID: 21657270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
    Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
    Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902.
    Struthers RS; Xie Q; Sullivan SK; Reinhart GJ; Kohout TA; Zhu YF; Chen C; Liu XJ; Ling N; Yang W; Maki RA; Bonneville AK; Chen TK; Bozigian HP
    Endocrinology; 2007 Feb; 148(2):857-67. PubMed ID: 17095587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
    Matsui H; Masaki T; Akinaga Y; Kiba A; Takatsu Y; Nakata D; Tanaka A; Ban J; Matsumoto S; Kumano S; Suzuki A; Ikeda Y; Yamaguchi M; Watanabe T; Ohtaki T; Kusaka M
    Eur J Pharmacol; 2014 Jul; 735():77-85. PubMed ID: 24747751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats.
    Anderes KL; Luthin DR; Castillo R; Kraynov EA; Castro M; Nared-Hood K; Gregory ML; Pathak VP; Christie LC; Paderes G; Vazir H; Ye Q; Anderson MB; May JM
    J Pharmacol Exp Ther; 2003 May; 305(2):688-95. PubMed ID: 12606616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relugolix for the treatment of uterine fibroids.
    Barra F; Seca M; Della Corte L; Giampaolino P; Ferrero S
    Drugs Today (Barc); 2019 Aug; 55(8):503-512. PubMed ID: 31461087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
    Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
    Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
    Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
    Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
    J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible downregulation of the hypothalamic-pituitary-gonadal axis in stallions with a novel GnRH antagonist.
    Davolli GM; Ball BA; Esteller-Vico A; Claes AN; Canisso IF; Fedorka CE; Woodward EM; Troedsson MH; Squires EL
    Theriogenology; 2016 Dec; 86(9):2272-2280. PubMed ID: 27570103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors.
    Tezuka M; Tamai Y; Kuramochi Y; Kobayashi K; Fushimi N; Kiguchi S
    Clin Exp Pharmacol Physiol; 2022 Oct; 49(10):1082-1093. PubMed ID: 35690889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist.
    Zou F; Wang Y; Yu D; Liu C; Lu J; Zhao M; Ma M; Wang W; Jiang W; Gao Y; Zhang R; Zhang J; Ye L; Tian J
    Eur J Med Chem; 2022 Nov; 242():114679. PubMed ID: 35998545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.